2019
Genetic Testing for Breast Cancer Susceptibility Should Be Offered before Unilateral Abdominally Based Free Flap Breast Reconstruction.
Dayan E, Chittenden A, Garber J, Wo L, Caterson S, Carty M, Erdmann-Sager J. Genetic Testing for Breast Cancer Susceptibility Should Be Offered before Unilateral Abdominally Based Free Flap Breast Reconstruction. Plastic & Reconstructive Surgery 2019, 144: 12-20. PMID: 31246791, DOI: 10.1097/prs.0000000000005693.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAtaxia Telangiectasia Mutated ProteinsBRCA2 ProteinBreast NeoplasmsCheckpoint Kinase 2Delivery of Health CareFanconi Anemia Complementation Group ProteinsFemaleFree Tissue FlapsGenetic Predisposition to DiseaseGenetic TestingHumansMammaplastyMastectomyMiddle AgedMutationRetrospective StudiesRNA HelicasesUbiquitin-Protein LigasesConceptsFree flap breast reconstructionFlap breast reconstructionBreast reconstructionGenetic testingDecreasing cost of genetic testingCost of genetic testingNational Comprehensive Cancer Network guidelinesWomen's Hospital/Dana-Farber Cancer InstitutePathogenic mutationsBreast cancer susceptibilityDeleterious genetic mutationsPercentage of patientsFollow-up periodHospital financial dataContralateral mastectomyContralateral surgeryATM mutationsCancer susceptibilityCost-effectiveNetwork guidelinesChart reviewInclusion criteriaBreast cancerFollow-upClinical dataPS1132 INHERITED DNA REPAIR AND CELL CYCLE GENE DEFECTS IN CHRONIC LYMPHOCYTIC LEUKEMIA
Moore N, Aldubayan S, Taylor‐Weiner A, Stilgenbauer S, Getz G, Wu C, Van Allen E, Brown J. PS1132 INHERITED DNA REPAIR AND CELL CYCLE GENE DEFECTS IN CHRONIC LYMPHOCYTIC LEUKEMIA. HemaSphere 2019, 3: 512-513. DOI: 10.1097/01.hs9.0000562812.55861.d4.Peer-Reviewed Original ResearchChronic lymphocytic leukemia patientsCell cycle genesChronic lymphocytic leukemiaDNA repairCycle genesVariant calling algorithmsCell cycle regulation pathwaysGenetically distinct cohortsLymphocytic leukemiaPathogenic ATM mutationQ-value <Calling algorithmsCHEK2 alterationsMutation enrichmentVariant enrichmentRisk genesPredisposition genesRegulation pathwaysMutation enrichment analysisCancer-free controlsEnrichment analysisATM mutationsGenesCase-control analysisCancer-free individualsInherited DNA repair and cell cycle gene defects in chronic lymphocytic leukemia.
Moore N, Aldubayan S, Taylor-Weiner A, Stilgenbauer S, Getz G, Wu C, Van Allen E, Brown J. Inherited DNA repair and cell cycle gene defects in chronic lymphocytic leukemia. Journal Of Clinical Oncology 2019, 37: 1508-1508. DOI: 10.1200/jco.2019.37.15_suppl.1508.Peer-Reviewed Original ResearchCell cycle genesChronic lymphocytic leukemia patientsDNA repairChronic lymphocytic leukemiaCycle genesVariant calling algorithmsCell cycle regulation pathwaysGenetically distinct cohortsPathogenic ATM mutationQ-value <Lymphocytic leukemiaCalling algorithmsCHEK2 alterationsMutation enrichmentVariant enrichmentRisk genesPredisposition genesRegulation pathwaysMutation enrichment analysisEnrichment analysisATM mutationsCancer-free controlsGenesGenetic heritabilityCase-control analysis
2017
Abstract 3807: ATM protein loss and clinical outcomes with platinum chemotherapy in patients with advanced solid tumors
Sundar R, Miranda S, Carreira S, Chénard-Poirier M, Rodrigues D, Figueiredo I, Bertan C, Yuan W, Perez D, Ferreira A, Tunariu N, Mateo J, Bono J. Abstract 3807: ATM protein loss and clinical outcomes with platinum chemotherapy in patients with advanced solid tumors. Cancer Research 2017, 77: 3807-3807. DOI: 10.1158/1538-7445.am2017-3807.Peer-Reviewed Original ResearchATM protein lossAdvanced solid tumorsPlatinum chemotherapyPlatinum therapyATM lossClinical outcomesMetastatic sitesATM mutationsIHC lossSolid tumorsNext generation sequencingAmerican Association for Cancer Research annual meetingsSensitivity to platinum therapySomatic ATM mutationsAdvanced solid cancersSites of patientsNuclear staining intensityRabbit monoclonal antibodyLoss of ATM expressionProtein lossColorectal cancer cohortDNA damage repair signalingTP53 mutationsArchival tumorsH-scoreTAX-TORC: A phase I trial of vistusertib (AZD2014) in combination with weekly paclitaxel with integrated pharmacodynamic (PD) and molecular characterization (MC) studies.
Sundar R, Basu B, Wilson R, Spicer J, Jones R, Krebs M, Brada M, Talbot D, Steele N, Hall E, Tovey H, Carreira S, de Oliveira F, Swales K, Balarajah G, Dawes J, Parmar M, De Bono J, Banerji U. TAX-TORC: A phase I trial of vistusertib (AZD2014) in combination with weekly paclitaxel with integrated pharmacodynamic (PD) and molecular characterization (MC) studies. Journal Of Clinical Oncology 2017, 35: 2571-2571. DOI: 10.1200/jco.2017.35.15_suppl.2571.Peer-Reviewed Original ResearchHigh-grade serous ovarian cancerHigh-grade serous ovarian cancer patientsRecommended phase 2 doseMedian progression free survivalImproving outcomes of patientsPhase 2 doseDose-limiting toxicityDose-escalation partProgression free survivalArchival tumor tissuePhase I trialSerous ovarian cancerOutcomes of patientsLines of treatmentResistance to chemotherapyP-S6K levelsPre-dose levelsPlatelet-rich plasmaWeekly paclitaxelExpansion cohortFree survivalPlatinum therapyATM mutationsLimiting toxicitiesBID PO
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply